GenVec's NIH link

CRADA is a mechanism by which a company can establish a long-term relationship with NIH. When properly nurtured, such collaborations can result in substantial value creation for the company. GenVec originally signed a CRADA with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases in October 2001. This CRADA was aimed at the development of adenoviral vectors expressing modified HIV-1 genes.

As the collaboration progressed, the relationship between GenVec and the NIH expanded to include ancillary contracts with a potential value of $30 million for manufacturing adenovector-based preventative AIDS and SARS vaccine candidates for the Vaccine Research Center. "In addition to the important revenue that these contracts provide, they help companies build infrastructure, further develop technology platforms, and gain valuable experience in manufacturing, quality and regulatory functions that may be applicable to other areas of their business," GenVec officials have stated.